Ablation plus systemic therapy for nasopharyngeal cancer spread to liver or lungs
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether combining local ablation (a procedure to destroy tumors) with systemic therapy (drugs that travel through the body) can help people whose nasopharyngeal cancer has spread to the liver or lungs. It may offer a way to control these secondary tumors and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have nasopharyngeal cancer that has spread to the liver and/or lungs, and the original tumor was treated at least 6 months ago.
- You have no more than 5 tumors in the liver/lungs, each 3 cm or smaller.
- You have not had chemotherapy (like gemcitabine plus cisplatin) or immunotherapy (PD-1 inhibitors) for the metastatic disease.
- You are generally in good health (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.